Understanding treatment resistance in prostate cancer @uclcancer. Tweets by Gert & team.
Joined January 2018
- Tweets248
- Following243
- Followers1.2K
- Likes55
AttardLab retweeted
About time! Good news for those men currently paying out of pocket for Abiraterone and great news for all men who will benefit in future. Well done @ProstateUK for your relentless campaigning to right this wrong.
BREAKING NEWS 📢
Abiraterone has been approved for use on the NHS for men in England with #ProstateCancer that has a high risk of spreading.
Over the next five years, this decision will save the lives of 3,000 men.
➡️ Read more: bit.ly/3NxcMYa
ALT Graphic stating: 'Abiraterone approved for more men in England', with a subtitle '3,000 lives saved in the next five years.'
AttardLab retweeted
Quick overview of news in Prostate Cancer from Esmo with @Ecastromarcos @AttardLab and Axel Heidenreich
Please follow ecancer.org/en/video/12526-b…
AttardLab retweeted
🚨 Big News from #APCCC26 🚨
APCCC is opening a Call for Abstracts, creating new opportunities for younger investigators & the next generation of leaders in advanced prostate cancer!
Full details & submission 👉 apccc.org
📅 Key Dates:
🔹 Submission opens: 1 Sept 2025
🔹 Deadline: 14 Nov 2025, 23:59 CET
🔹 Notifications: 19 Dec 2025
✅ Complimentary registration for presenting authors. ✅ Travel grants available for LMIC investigators.
✅ Selected abstracts will be presented as posters in Lugano (30 Apr–1 May 2026).
Categories:
Advanced prostate cancer
Side effects & QoL/PROs
Global access to therapies
@Silke_Gillessen & @AOmlin
@OncoAlert 🚨
@fabioturco92
@Prof_IanD
@drjefstathiou
@Prof_Nick_James
@ChrisSweens1
@BertrandTOMBAL
@ZilliThomas
@neerajaiims
@bjartell
@PBlanchardMD
@BourlonMaite
@Albert0Briganti
@cdanicas
@Ecastromarcos
@mdesantis234
@nachoduranm
@drlouiseemmett
@stefanofanti4
@fontev1
@Nicola_Fossati
@marty_gleave
@ProfKHerrmann
@DrMHofman
@BarbaraJereczek
@ravikanesvaran
@FacsRaja
@LoebStacy
@quimmateo
@DrRanaMcKay
@amerseburger
@CaPsurvivorship
@declangmurphy
@DrPaulNguyen
@WilliamOhMD
@piet_ost
@DrSpratticus
@cnsternberg
@DrYukselUrun
@DrChoueiri
@tompowles1
@brian_rini
Ping
@nataliagandur
@bavilima
@yekeduz_emre
AttardLab retweeted
The mHSPC space becomes more and more interesting! Come and participate in the discussions @APCCC_Lugano register via apccc.org!
Capivasertib plus abiraterone in PTEN-deficient metastatic hormone-sensitive prostate cancer: CAPItello-281 Phase III study out on Annals of Oncology
annalsofoncology.org/article…
CAPItello-281
In PTEN-deficient metastatic hormone-sensitive #ProstateCancer , adding the AKT inhibitor capivasertib to abiraterone and ADT significantly prolonged radiographic progression-free survival with manageable, expected toxicities.
Karim Fizazi
@mdesantis234
@M_SoteloLezama
@Daniel_J_George
@OncoAlert 🚨
@silkegillessen
@AOmlin
@nataliagandur
@bavilima
AttardLab retweeted
@AzadOncology asking the question- do all patients need six cycles of Lu-PSMA in #PSMAaddition? Showing a nice example of complete response after two cycles on #UpFrontPSMA – at Berlin, Germany
AttardLab retweeted
CAPItello-281
In de novo PTEN-deficient mHSPC (poor prognosis), capivasertib + abiraterone ↑ rPFS vs pbo + abiraterone (33.2 vs 25.7 mo; HR 0.81; P=0.034), OS immature. ↑ PTEN loss correlated with ↑ benefit; POTENTIAL for now
With Amplitude trial paving the way, NGS is key in mHSPC
How should we integrate this combo when triplet is already available?
@OncoAlert @myESMO #ESMO25
#ESMO25
Ph III CAPItello 281: Capivasertib + Abiraterone vs pbo + Abi in PTEN-deficient de novo mHSPC
rPFS 33.2 vs 25.7 mo (HR 0.81); OS not yet mature ⚠️
A promising first in class targeted option for this poor-prognosis population
Benefit ↑ w/greater PTEN loss, emphasizing the need for biomarker based 1L treatment as seen with BRCA/HRR @OncoAlert
AttardLab retweeted
Wonderful discussion by @Prof_Nick_James on EnzaRad highlighting the differences between Stampede. Lower risk group enrolled and differential effect of ARPI in higher risk group. #ESMO25 @myESMO @OncoAlert
AttardLab retweeted
ALBAN #ESMO25 (atezolizumab/BCG vs BCG in MIBC) @Annals_Oncology did not ⬆️ EFS (HR0.97) unlike sasalimab & durvalumab in a similar setting. The drugs seem similar in metastatic UC so was it trial design making it different from other ICIs? EFS was defined differently.
AttardLab retweeted
Precision medicine enters hormone sensitive prostate cancer therapeutics !
The first of many to follow
💫🌟Niraparib + Abiraterone + Prednisone in HRR-deficient mCSPC.🌟💫 nature.com/articles/s41591-0… @AttardLab @neerajaiims @SandhuShahneen @EfstathiouEleni @drgotto @heatherhcheng @Dolmos77 @drenriquegrande @DRathkopf
@uclcancer @huntsmancancer @seattlecca @fredhutch @uwmedicine @PCF_Science @sloan_kettering
@OncoAlert
💥 First Phase III evidence of PARP inhibition in mCSPC!
🔹 Design: Double-blind, randomized (n=696), HRR+ (56% BRCA1/2)
🔹 Primary endpoint met:
• rPFS HR 0.52 (BRCA) → NE vs 26 mo
• rPFS HR 0.63 (ITT) → NE vs 29.5 mo
🔹 Time to symptomatic progression HR 0.50
🔹 OS (immature): HR 0.79, trend favoring niraparib
🔹 Toxicities: Anemia 29%, Hypertension 27%, manageable
🔹 HRR testing now essential at mCSPC diagnosis
🧠 Clinical impact:
Niraparib + Abiraterone delivers significant PFS improvement in BRCA1/2 mCSPC—marking the PARPi era’s entry into hormone-sensitive disease.
@myESMO @ASCO @UroToday @NatureMedicine @Uromigos
#ProstateCancer #mCSPC #HRR #PARPi #Niraparib #PrecisionOncology #GUOnc #OncoTwitter
AttardLab retweeted
Please share with all interested colleagues!
🚨 Big News from #APCCC26 🚨
APCCC is opening a Call for Abstracts, creating new opportunities for younger investigators & the next generation of leaders in advanced prostate cancer!
Full details & submission 👉 apccc.org
📅 Key Dates:
🔹 Submission opens: 1 Sept 2025
🔹 Deadline: 14 Nov 2025, 23:59 CET
🔹 Notifications: 19 Dec 2025
✅ Complimentary registration for presenting authors. ✅ Travel grants available for LMIC investigators.
✅ Selected abstracts will be presented as posters in Lugano (30 Apr–1 May 2026).
Categories:
Advanced prostate cancer
Side effects & QoL/PROs
Global access to therapies
@Silke_Gillessen & @AOmlin
@OncoAlert 🚨
@fabioturco92
@Prof_IanD
@drjefstathiou
@Prof_Nick_James
@ChrisSweens1
@BertrandTOMBAL
@ZilliThomas
@neerajaiims
@bjartell
@PBlanchardMD
@BourlonMaite
@Albert0Briganti
@cdanicas
@Ecastromarcos
@mdesantis234
@nachoduranm
@drlouiseemmett
@stefanofanti4
@fontev1
@Nicola_Fossati
@marty_gleave
@ProfKHerrmann
@DrMHofman
@BarbaraJereczek
@ravikanesvaran
@FacsRaja
@LoebStacy
@quimmateo
@DrRanaMcKay
@amerseburger
@CaPsurvivorship
@declangmurphy
@DrPaulNguyen
@WilliamOhMD
@piet_ost
@DrSpratticus
@cnsternberg
@DrYukselUrun
@DrChoueiri
@tompowles1
@brian_rini
Ping
@nataliagandur
@bavilima
@yekeduz_emre
AttardLab retweeted
🚨 Big News from #APCCC26 🚨
APCCC is opening a Call for Abstracts, creating new opportunities for younger investigators & the next generation of leaders in advanced prostate cancer!
Full details & submission 👉 apccc.org
📅 Key Dates:
🔹 Submission opens: 1 Sept 2025
🔹 Deadline: 14 Nov 2025, 23:59 CET
🔹 Notifications: 19 Dec 2025
✅ Complimentary registration for presenting authors. ✅ Travel grants available for LMIC investigators.
✅ Selected abstracts will be presented as posters in Lugano (30 Apr–1 May 2026).
Categories:
Advanced prostate cancer
Side effects & QoL/PROs
Global access to therapies
@Silke_Gillessen & @AOmlin
@OncoAlert 🚨
@fabioturco92
@Prof_IanD
@drjefstathiou
@Prof_Nick_James
@ChrisSweens1
@BertrandTOMBAL
@ZilliThomas
@neerajaiims
@bjartell
@PBlanchardMD
@BourlonMaite
@Albert0Briganti
@cdanicas
@Ecastromarcos
@mdesantis234
@nachoduranm
@drlouiseemmett
@stefanofanti4
@fontev1
@Nicola_Fossati
@marty_gleave
@ProfKHerrmann
@DrMHofman
@BarbaraJereczek
@ravikanesvaran
@FacsRaja
@LoebStacy
@quimmateo
@DrRanaMcKay
@amerseburger
@CaPsurvivorship
@declangmurphy
@DrPaulNguyen
@WilliamOhMD
@piet_ost
@DrSpratticus
@cnsternberg
@DrYukselUrun
@DrChoueiri
@tompowles1
@brian_rini
Ping
@nataliagandur
@bavilima
@yekeduz_emre
AttardLab retweeted
Could transcriptome signatures identify men with advanced #ProstateCancer most likely to benefit from chemotherapy?
A brilliant team led by @AttardLab @uclcancer share exciting new findings in @CellCellPress.
Grab a ☕ and read: doi.org/10.1016/j.cell.2025.…
ALT Scientific Paper Published in Cell, titled: Tumor transcriptome-wide expression classifiers predict treatment sensitivity in advanced prostate cancers. Written by Grist et al.
AttardLab retweeted
Today is my last day @AttardLab @uclcancer! I’ve had a brilliant time. Been lucky enough to work with lovely people on interesting projects and have learnt a LOT. I’m excited to join @NATCAN_news as senior project manager on newly funded cancer audits rcseng.ac.uk/standards-and-r…
AttardLab retweeted
Great all day meeting of the STAMPEDE Translational Research Group. So much great work: imaging, pathology, DNA & RNA profiling, big data mining of NHS data. Big papers pending 😊 @ICR_London @MRCCTU @CRUKresearch @ProstateUK @AttardLab – at Paddington, London
AttardLab retweeted
Interesting genomic data from STAMPEDE particularly M0 patients. Can we avoid abiraterone safely in low genomic but high clinical risk M0 HSPC patients? #ESMO2022 interactions not significant but absolute benefits lower.
AttardLab retweeted
1 week to go until our Experts Knowledge Share: 'Targeting Advanced #ProstateCancer with PARP inhibitors: Who, When and Why?'
Join the discussion with Drs. Fred Saad, Tanya Dorff @TDorffOnc and Gerhardt Attard @AttardLab
Book your place here:👉bit.ly/3HGrjIJ
Join the discussion at our virtual Experts Knowledge Share on;
-Efficacy & safety profiles of PARP inhibitors
-Testing strategies to predict PARP inhibitor suitability
-Data of combination studies with PARP inhibitors
register: ow.ly/g8gv50HQFOQ
#MedEd @TDorffOnc @AttardLab
AttardLab retweeted
15 min podcast in conversation with @thelancet on the latest STAMPEDE results plus a commentary on the trial structure, adding arms to trials and broader implications for clinical trials in general
thelancet.com/in-conversatio… @ICR_London @MRCCTU @CR_UK @cancerBRC
AttardLab retweeted
Well said Nick. A very good time to thank you for all the hard work you do behind the scenes to ensure that the study has been so successful. 🏴 💪 Hope you are able to have a very well deserved break 🇧🇷 @mattsydes @Silke_Gillessen @PCaParker @MaxParmarMRCUCL Thank you 🙏
I would very much echo this. A huge effort by all concerned with massively important results. The outcomes emphasise why we have been campaigning to maintain trial recruitment during the Pandemic @ICR_London @royalmarsdenNHS @cancerBRC